Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 156

1.

Neutralizing antibodies are associated with a reduction of interferon-β efficacy during the treatment of Japanese multiple sclerosis patients.

Sato DK, Nakashima I, Fukazawa T, Shimizu Y, Tomizawa Y, Yokoyama K, Misu T, Creeke PI, Farrell R, Giovannoni G, Itoyama Y, Fujihara K, Aoki M.

Tohoku J Exp Med. 2012;228(2):85-92.

2.

Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b.

Antonelli G, Simeoni E, Bagnato F, Pozzilli C, Turriziani O, Tesoro R, Di Marco P, Gasperini C, Fieschi C, Dianzani F.

J Neurol Sci. 1999 Oct 15;168(2):131-6.

PMID:
10526196
3.

Human leukocyte antigen genes and interferon beta preparations influence risk of developing neutralizing anti-drug antibodies in multiple sclerosis.

Link J, Lundkvist Ryner M, Fink K, Hermanrud C, Lima I, Brynedal B, Kockum I, Hillert J, Fogdell-Hahn A.

PLoS One. 2014 Mar 7;9(3):e90479. doi: 10.1371/journal.pone.0090479. eCollection 2014.

4.

Antibodies to interferon beta in patients with multiple sclerosis receiving CinnoVex, rebif, and betaferon.

Zare N, Zarkesh-Esfahani SH, Gharagozloo M, Shaygannejad V.

J Korean Med Sci. 2013 Dec;28(12):1801-6. doi: 10.3346/jkms.2013.28.12.1801. Epub 2013 Nov 26.

5.

Neutralizing antibodies to interferon.

Noronha A.

Neurology. 2007 Jun 12;68(24 Suppl 4):S16-22. Review.

PMID:
17562846
6.
7.

Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study.

Kappos L, Clanet M, Sandberg-Wollheim M, Radue EW, Hartung HP, Hohlfeld R, Xu J, Bennett D, Sandrock A, Goelz S; European Interferon Beta-1a IM Dose-Comparison Study Investigators.

Neurology. 2005 Jul 12;65(1):40-7.

PMID:
16009883
8.

Inhibition of endogenous interferon beta by neutralizing antibodies against recombinant interferon beta.

Sominanda A, Lundkvist M, Fogdell-Hahn A, Hemmer B, Hartung HP, Hillert J, Menge T, Kieseier BC.

Arch Neurol. 2010 Sep;67(9):1095-101. doi: 10.1001/archneurol.2010.218.

PMID:
20837854
9.

Neutralizing antibodies explain the poor clinical response to interferon beta in a small proportion of patients with multiple sclerosis: a retrospective study.

Sbardella E, Tomassini V, Gasperini C, Bellomi F, Cefaro LA, Morra VB, Antonelli G, Pozzilli C.

BMC Neurol. 2009 Oct 13;9:54. doi: 10.1186/1471-2377-9-54.

10.

Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study.

Pachner AR, Cadavid D, Wolansky L, Skurnick J.

Neurology. 2009 Nov 3;73(18):1485-92. doi: 10.1212/WNL.0b013e3181bf9919.

PMID:
19884576
12.

Cell-based reporter gene assay for therapy-induced neutralizing antibodies to interferon-beta in multiple sclerosis.

Martins TB, Rose JW, Gardiner GL, Kusukawa N, Husebye D, Hill HR.

J Interferon Cytokine Res. 2013 Feb;33(2):52-7. doi: 10.1089/jir.2012.0027. Epub 2012 Nov 15.

PMID:
23153300
13.

Incorporation of an interferon-β neutralizing antibody assay into routine clinical practice.

Farrell RA, Espasandin M, Lakdawala N, Creeke PI, Worthington V, Giovannoni G.

Mult Scler. 2011 Nov;17(11):1333-40. doi: 10.1177/1352458511412654. Epub 2011 Jun 17.

PMID:
21685230
14.

Optimising MS disease-modifying therapies: antibodies in perspective.

Giovannoni G.

J Neurol. 2004 Sep;251 Suppl 5:v30-v35. Review.

PMID:
15549353
15.

The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.

Koch-Henriksen N, Sorensen PS, Bendtzen K, Flachs EM.

Mult Scler. 2009 May;15(5):601-5. doi: 10.1177/1352458508101946. Epub 2009 Mar 19.

PMID:
19299439
16.

Appearance and disappearance of neutralizing antibodies during interferon-beta therapy.

Sorensen PS, Koch-Henriksen N, Ross C, Clemmesen KM, Bendtzen K; Danish Multiple Sclerosis Study Group.

Neurology. 2005 Jul 12;65(1):33-9. Epub 2005 May 11.

PMID:
15888603
17.

Interferon β-1b-neutralizing antibodies 5 years after clinically isolated syndrome.

Hartung HP, Freedman MS, Polman CH, Edan G, Kappos L, Miller DH, Montalbán X, Barkhof F, Petkau J, White R, Sahajpal V, Knappertz V, Beckmann K, Lanius V, Sandbrink R, Pohl C; BENEFIT Study Group.

Neurology. 2011 Aug 30;77(9):835-43. doi: 10.1212/WNL.0b013e31822c90d7. Epub 2011 Aug 17. Erratum in: Neurology. 2011 Sep 27;77(13):1317.

PMID:
21849647
18.

Single-nucleotide polymorphisms in HLA- and non-HLA genes associated with the development of antibodies to interferon-β therapy in multiple sclerosis patients.

Weber F, Cepok S, Wolf C, Berthele A, Uhr M, Bettecken T, Buck D, Hartung HP, Holsboer F, Müller-Myhsok B, Hemmer B.

Pharmacogenomics J. 2012 Jun;12(3):238-45. doi: 10.1038/tpj.2011.14. Epub 2011 Apr 19.

PMID:
21502966
19.

Neutralizing antibodies to interferon-beta and other immunological treatments for multiple sclerosis: prevalence and impact on outcomes.

Deisenhammer F.

CNS Drugs. 2009;23(5):379-96. doi: 10.2165/00023210-200923050-00003. Review.

PMID:
19453200
20.

Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG)

Rudick RA, Simonian NA, Alam JA, Campion M, Scaramucci JO, Jones W, Coats ME, Goodkin DE, Weinstock-Guttman B, Herndon RM, Mass MK, Richert JR, Salazar AM, Munschauer FE 3rd, Cookfair DL, Simon JH, Jacobs LD.

Neurology. 1998 May;50(5):1266-72.

PMID:
9595973
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk